China-based Shanghai Henlius Biotech Inc (2696.HK) and Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals Ltd, have received approval from the European Commission (EC) for their Zercepac, a biosimilar, trastuzumab, intended for the treatment of certain patients with HER2-positive early breast cancer, HER2-positive metastatic breast cancer and earlier untreated HER2-positive metastatic gastric cancer, it was reported on Wednesday.
The product received approval based on a series of studies including comparative quality studies, preclinical and clinical studies.
Zercepac was developed and produced by Henlius and is the first monoclonal antibody (mAb) and third biosimilar, launched by Accord in Europe, and is the first mAb developed by Henlius to be approved in the European Union.
US FDA accepts Advicenne's NDA for Sibnayal to treat dRTA
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
European Commission approves Sobi's Aspaveli for rare kidney diseases
US FDA accepts IND application for AskBio's AB-1009
EspeRare and n-Lorem partner to expand European access to ASO therapies for rare genetic diseases
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer